HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roos, Y. Search for Related Content PubMed PubMed Citation Articles by Roos, Y.

Antifibrinolytic treatment in subarachnoid hemorrhage

A randomized placebo-controlled trial

From the Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands.

Address correspondence and reprint requests to Dr. M. Vermeulen, Department of Neurology, Academic Medical Center (AMC), University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, the Netherlands; e-mail: m.vermeulen{at}amc.uva.nl

OBJECTIVE: To investigate whether antifibrinolytics in combination with treatment to prevent cerebral ischemia improve outcome in patients with subarachnoid hemorrhage (SAH) in whom occlusion of the aneurysm is delayed.

BACKGROUND: Antifibrinolytic treatment reduces rebleeding, but outcome does not improve because of a concurrent increase in the occurrence of cerebral ischemia. Because treatment of ischemia has improved, antifibrinolytics might now have a beneficial effect.

METHODS: A prospective, double-blind, placebo-controlled multicenter clinical trial was performed. Randomized were 462 patients (229 received tranexamic acid, 233 placebo) admitted within 96 hours after onset of SAH, in whom treatment of the aneurysm was delayed beyond 48 hours after SAH. All patients were treated with calcium antagonists and hypervolemia. At 3 months, outcome was assessed with the Glasgow Outcome Scale. The occurrence of cerebral ischemia and other complications were recorded, and the effects of treatment were related to the clinical condition on admission.

RESULTS: Antifibrinolytic treatment had no beneficial effect on outcome (relative risk [RR], 1.10; 95% confidence limits [CL], 0.91–1.34). Antifibrinolytics significantly reduced the occurrence of rebleeding (RR, 0.58; 95% CL, 0.42–0.80); the occurrence of ischemic and other complications was the same in the two groups.

CONCLUSION: Antifibrinolytic treatment combined with treatment to prevent cerebral ischemia does not improve outcome.

Key words: Subarachnoid hemorrhage—Antifibrinolytic treatment—Randomized trial

This article has been cited by other articles:

				H.-J. Priebe Aneurysmal subarachnoid haemorrhage and the anaesthetist Br. J. Anaesth., July 1, 2007; 99(1): 102 - 118. [Abstract] [Full Text] [PDF]

				C. A. Hellingman, W. M. van den Bergh, I. S. Beijer, G. W. van Dijk, A. Algra, J. van Gijn, and G. J.E. Rinkel Risk of Rebleeding After Treatment of Acute Hydrocephalus in Patients With Aneurysmal Subarachnoid Hemorrhage Stroke, January 1, 2007; 38(1): 96 - 99. [Abstract] [Full Text] [PDF]

				D J Nieuwkamp, G J E Rinkel, R Silva, P Greebe, D A Schokking, and J M Ferro Subarachnoid haemorrhage in patients >=75 years: clinical course, treatment and outcome J. Neurol. Neurosurg. Psychiatry, August 1, 2006; 77(8): 933 - 937. [Abstract] [Full Text] [PDF]

				Y.B.W.E.M. Roos, G. Pals, P.M. Struycken, G.J.E. Rinkel, M. Limburg, J.C. Pronk, J.S.P. van den Berg, J.A.F.M. Luijten, P.L. Pearson, M. Vermeulen, et al. Genome-Wide Linkage in a Large Dutch Consanguineous Family Maps a Locus for Intracranial Aneurysms to Chromosome 2p13 Stroke, October 1, 2004; 35(10): 2276 - 2281. [Abstract] [Full Text] [PDF]

				M.D.I. Vergouwen, C.J.M. Frijns, Y.B.W.E.M. Roos, G.J.E. Rinkel, F. Baas, and M. Vermeulen Plasminogen Activator Inhibitor-1 4G Allele in the 4G/5G Promoter Polymorphism Increases the Occurrence of Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage Stroke, June 1, 2004; 35(6): 1280 - 1283. [Abstract] [Full Text] [PDF]

				R Schats, E H Brilstra, G J E Rinkel, A Algra, and J van Gijn Informed consent in trials for neurological emergencies: the example of subarachnoid haemorrhage J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 988 - 991. [Abstract] [Full Text] [PDF]

				Y.B.W.E.M. Roos, M. Levi, T. A. Carroll, L.F.M. Beenen, and M. Vermeulen Nimodipine Increases Fibrinolytic Activity in Patients With Aneurysmal Subarachnoid Hemorrhage Stroke, August 1, 2001; 32(8): 1860 - 1862. [Abstract] [Full Text] [PDF]

				J. van Gijn and G. J. E. Rinkel Subarachnoid haemorrhage: diagnosis, causes and management Brain, February 1, 2001; 124(2): 249 - 278. [Abstract] [Full Text] [PDF]

				Subarachnoid Hemorrhage: Can We Stop the Bleeding? Journal Watch Emergency Medicine, April 1, 2000; 2000(401): 3 - 3. [Full Text]